Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SURPASS: ELA026 in Secondary Hemophagocytic Lymphohistiocytosis (sHLH)
NCT05416307Phase 3Recruiting
- Sponsor
- Electra Therapeutics
- Start
- May 2022
- Primary completion
- Mar 2028
- Modality
- Monoclonal Antibodies
- Countries
- 7
01
Overview
A Phase 3 trial of ELA026 in haemophagocytic lymphohistiocytosis (HLH), sponsored by Electra Therapeutics. Started May 2022; status: recruiting.
02
Drugs
ELA026
03
Conditions
haemophagocytic lymphohistiocytosis (HLH)
Beyond the preview
Go deeper on NCT05416307.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05416307.